跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 3,288 条关于
“MuSK myasthenia gravis”
全部
3,288
临床试验
2,166
药物
77
机构
26
资讯
1,019
去年
NMD Pharma Presents Preclinical Data on ClC-1 Ion Channel Inhibition for MuSK Myasthenia Gravis Treatment
去年
Inebilizumab Shows Promise in Myasthenia Gravis, Phase 3 Data Suggests
8个月前
GlycoEra Appoints Petra Duda as Chief Medical Officer to Lead Precision Protein Degrader Pipeline
去年
Cabaletta Bio to Present New CABA-201 Clinical Data at ACR Convergence 2024
9个月前
FDA Approves UPLIZNA as First CD19-Targeted B Cell Therapy for Generalized Myasthenia Gravis
去年
Myasthenia Gravis Market Set to Reach $10.3 Billion by 2034 Driven by Seven Late-Stage Pipeline Therapies
去年
Amgen's Uplizna Shows Promise in Myasthenia Gravis Trial, Rocatinlimab Data Disappoints
去年
Nipocalimab Receives FDA Priority Review for Generalized Myasthenia Gravis Treatment
去年
KYV-101 Receives Orphan Drug Status in Europe for Myasthenia Gravis
10个月前
Johnson & Johnson Launches First Head-to-Head FcRn Blocker Study in Myasthenia Gravis
第 1 页,共 102 页
上一页
下一页